Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
Open Access
- 26 February 2021
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (2), e001696
- https://doi.org/10.1136/jitc-2020-001696
Abstract
Background The advent of immune checkpoint therapy has been a tremendous advance in cancer treatment. However, the responses are still insufficient in patients with soft tissue sarcoma (STS). We aimed to identify rational combinations to increase the response to immune checkpoint therapy and improve survival. Methods Whole-exome sequencing (WES) was performed in 11 patients with liposarcoma. Somatic copy number alterations (SCNAs) were analyzed at the gene level to identify obvious amplification patterns in drug-target genes. The expression and prognostic value of class I histone deacetylases (HDACs) was evaluated in 49 patients with sarcoma in our center and confirmed in 263 sarcoma samples from The Tumor Cancer Genome Atlas (TCGA) database. Q-PCR, flow cytometry and RNA-seq were performed to determine the correlations between class I HDACs, chidamide and PD-L1 in vitro and in vivo. The efficacy of combining chidamide with PD-1 blockade was explored in an immunocompetent murine model and a small cohort of patients with advanced sarcoma. Western blot, ChIP assay and dual luciferase assessment were applied in the mechanistic study. Results The HDAC gene family was frequently amplified in STS. SCNAs in the HDAC gene family were extensively amplified in 8 of 11 (73%) patients with liposarcoma, based on a drug-target gene set, and we verified amplification in 76.65% (197/257) of cases by analyzing TCGA sarcoma cohort. Class I HDAC expression is associated with a poor prognosis for patients with STS, and its inhibition is responsible for promoting apoptosis and upregulating of programmed cell death ligand 1 (PD-L1). The HDAC class I inhibitor chidamide significantly increases PD-L1 expression, increased the infiltration of CD8+ T cells and reduced the number of MDSCs in the tumor microenvironment. The combination of chidamide with an anti-PD-1 antibody significantly promotes tumor regression and improves survival in a murine model. Moreover, chidamide combined with the anti-PD-1 antibody toripalimab is effective in patients with advanced and metastatic sarcoma, and the side effects are tolerable. Mechanistically, chidamide increases histone acetylation at the PD-L1 gene through the activation of the transcriptional factor STAT1. Conclusions The combination of chidamide and anti-programmed cell death 1 (PD-1) therapy represents a potentially important strategy for STS.Funding Information
- National Scientific Foundation of China (81572403)
- National Key Research and Dvelopment Program of China (2017YFA0505600)
- National Scientific Foundation of China (81772863)
- National Scientific Foundation of China (82002835)
This publication has 43 references indexed in Scilit:
- HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKTCancer Research, 2014
- Quantitative Analysis of Copy Number Variants Based on Real‐Time LightCycler PCRCurrent Protocols in Human Genetics, 2014
- Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue SarcomasPLOS ONE, 2013
- Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer ModelsPLOS ONE, 2012
- Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodiesProceedings of the National Academy of Sciences of the United States of America, 2011
- Trends in survival for patients with metastatic soft‐tissue sarcomaCancer, 2010
- FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell LymphomaThe Oncologist, 2007
- Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin‐3AInternational Journal of Cancer, 2007
- Evaluation of MDM2 and CDK4 amplification by real‐time PCR on paraffin wax‐embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well‐differentiated liposarcomasThe Journal of Pathology, 2003
- Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor αInternational Journal of Cancer, 2003